Spyre Therapeutics, Inc. (3920)
XDUS
Closed
Aug 24, 2026
Day's Range
89.5052 wk Range
12.20Overview - 3920 - Spyre Therapeutics, Inc.
Key Statistics
Valuation
P/E (Trailing)
‪-45.95‬
PEG Ratio
‪1.54‬
Price / Book
‪7.03‬
Profitability
Return on Assets
‪-19.95%‬
Return on Equity
‪-21.69%‬
Ownership
Shares Outstanding
88.06M
Price stats
50-Day Avg
‪83.21‬
200-Day Avg
‪50.52‬
Peers - 3920 - Spyre Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 3920XDUSSpyre Therapeutics, Inc.+84.37%52-week change-46.21P/E (Trailing)—Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+86.32%52-week change-2.62P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.81%52-week change-30.12P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.20%52-week change-22.50P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.55%52-week change—P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.54%52-week change—P/E (Trailing)—Profit Margin
- 7BGXDUSOncoinvent ASA+75.21%52-week change-0.06P/E (Trailing)—Profit Margin
Profile Summary - 3920 - Spyre Therapeutics, Inc.
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies target validated mechanisms to address inflammatory bowel disease (IBD)…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
